查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1775440

全球支氣管擴張劑市場：2025-2030 年預測

Global Bronchodilator Drug Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球支氣管擴張劑市場預計將從 2025 年的 451.11 億美元成長到 2030 年的 562.75 億美元，複合年成長率為 4.52%。

本研究報告為尋求市場趨勢、競爭格局和成長機會等切實可行的洞察的行業專業人士，提供了關於支氣管擴張劑治療領域不斷發展的全面分析。該研究深入探討了市場結構，並檢視了影響其發展軌跡的關鍵細分市場、地區和最新發展動態。報告涵蓋了新冠疫情 (COVID-19) 等全球健康挑戰的影響，並詳細闡述了市場促進因素、限制因素和競爭策略。透過關注疾病類型、給藥途徑和不同地區市場差異等關鍵領域，本支氣管擴張劑市場研究為相關人員提供了駕馭這個複雜而充滿活力的行業的寶貴知識。

市場概況和範圍

支氣管擴張劑市場涵蓋緩解氣喘和慢性阻塞性肺病(COPD) 等呼吸系統疾病引起的氣道阻塞的治療方法。本研究透過分析疾病類型（氣喘、COPD 等）和給藥途徑（口服、注射、劑量、吸入）等關鍵細分市場來定義市場。研究也評估了北美、歐洲、亞太、南美以及中東和非洲等主要地區的市場動態。支氣管擴張劑市場顯示，呼吸系統疾病盛行率的上升、藥物輸送系統的進步以及醫療保健投資的增加是推動其成長的因素，而監管挑戰和學名藥的競爭則是限制因素。

調查方法

該調查方法嚴格結合了來自行業相關人員的原始數據以及來自監管文件、臨床試驗和市場報告的二手數據。此外，我們也透過專家諮詢檢驗假設，以確保準確性。該研究整合了波特五力模型和產業價值鏈分析，旨在提供市場競爭力和商業框架的整體情況。

市場動態

研究指出，吸入器和生技藥品的日益普及是市場的主要驅動力，這得益於其功效和患者依從性。然而，高昂的研發成本和嚴格的生技藥品要求也構成了限制因素。競爭對手之間的競爭非常激烈，領先的企業紛紛投資於新型療法並建立策略聯盟以維持市場佔有率。產業價值鏈分析強調了原料供應商、製造商和經銷商在確保產品供應方面的關鍵作用。

市場區隔分析

支氣管擴張劑市場根據疾病類型和給藥途徑進行細分。氣喘和慢性阻塞性肺病 (COPD) 因其高發病率而佔據疾病類型細分市場的主導地位，而吸入式藥物因其靶向給藥和快速起效而佔據給藥途徑細分市場的主導地位。按地區分類，受先進的醫療基礎設施和高疾病負擔的推動，北美佔據最大佔有率；而亞太地區則因人們意識的提高和醫療可及性的改善而呈現快速成長。

競爭格局與分析

支氣管擴張劑市場競爭激烈，葛蘭素史克、阿斯特捷利康和諾華等主要企業尤其突出。近期發展凸顯了這些公司為加強其產品組合所採取的策略性舉措。例如，葛蘭素史克已在多個地區擴大其用於治療 COPD 的三重吸入複合劑 Trelegy Ellipta 的核准，從而加強了其市場滲透率。同樣，阿斯特捷利康用於治療重度氣喘的生物製藥Fasenra 也有新的臨床數據顯示其具有抑制氣喘發作的功效，使其成為氣喘領域的有力競爭者。此類創新凸顯了對個人化治療和聯合治療的關注。該研究還檢視了維羅納製藥等新創新興企業，該公司正在開發用於治療 COPD 的安西芬特林霧化療法，並可能透過新的作用機制顛覆市場。透過供應商競爭矩陣檢驗，併購和聯盟（例如諾華的數位健康整合合作夥伴關係）進一步加劇了競爭。

公司簡介

羅氏公司、吉利德科學公司、默克、輝瑞和雅培等主要企業的詳細資料，有助於深入了解其策略、產品平臺和市場定位。這些公司簡介重點介紹了公司如何利用研發、監管核准和地理擴張來維持支氣管擴張劑市場的成長。

本報告的主要優點

  • 深刻分析：獲得深入的市場洞察，重點關注客戶細分、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場，涵蓋主要地區和新興地區。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響市場的未來發展。
  • 可行的建議：利用洞察力進行策略決策，在動態環境中開闢新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問公司、中小企業和大型企業都有益且具有成本效益。

它有什麼用途？

產業與市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

  • 2022 年至 2024 年的實際數據和 2025 年至 2030 年的預測數據
  • 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
  • 競爭定位、策略與市場佔有率分析
  • 收益成長和預測細分市場和區域分析（包括國家）
  • 公司概況（策略、產品、財務、主要發展等）

目錄

第1章 引言

  • 市場概覽
  • COVID-19的影響
  • 市場定義
  • 市場區隔

第2章調查方法

  • 調查數據
  • 先決條件

第3章執行摘要

  • 調查重點

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 業內競爭對手之間的競爭
  • 產業價值鏈分析

第5章全球支氣管擴張劑市場依疾病類型分析

  • 介紹
  • 氣喘
  • 慢性阻塞性肺病（COPD）
  • 其他

6. 全球支氣管擴張劑市場依給藥途徑分析

  • 介紹
  • 口服
  • 注射
  • 吸入器

7. 全球支氣管擴張劑市場區域分析

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 以色列
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 印度
    • 泰國
    • 台灣
    • 印尼
    • 其他

第8章競爭格局及分析

  • 主要企業和策略分析
  • 新興企業和市場盈利
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第9章 公司簡介

  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • Novartis AG
  • Verona Pharma plc
  • Pfizer Inc.
  • Abbott
  • AstraZeneca plc
簡介目錄
Product Code: KSI061613440

The Global Bronchodilator Drug Market is expected to grow from USD 45.111 billion in 2025 to USD 56.275 billion in 2030, at a CAGR of 4.52%.

The Global Bronchodilator Drug Market study provides a comprehensive analysis of the evolving landscape of bronchodilator therapies, targeting industry experts seeking actionable insights into market trends, competitive dynamics, and growth opportunities. This research delves into the market's structure, examining key segments, geographic regions, and recent developments that shape its trajectory. The study addresses the impact of global health challenges, such as COVID-19, and offers a detailed perspective on market drivers, restraints, and competitive strategies. By focusing on critical areas like disease types, administration routes, and regional market variations, the Global Bronchodilator Drug Market study equips stakeholders with the knowledge to navigate this complex and dynamic industry.

Market Overview and Scope

The bronchodilator drug market encompasses therapies designed to relieve airway obstruction in respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). The study defines the market by analyzing key segments, including disease types (asthma, COPD, and others) and routes of administration (oral, injection, debate, and inhaler). It also evaluates the market dynamics across major regions, such as North America, Europe, Asia Pacific, South America, and the Middle East and Africa. The Global Bronchodilator Drug Market highlights how rising prevalence of respiratory diseases, advancements in drug delivery systems, and increasing healthcare investments drive growth, while regulatory challenges and generic competition pose restraints.

Research Methodology

The research employs a rigorous methodology, combining primary data from industry stakeholders with secondary data from regulatory filings, clinical studies, and market reports. Assumptions are validated through expert consultations to ensure accuracy. The study integrates Porter's Five Forces and industry value chain analyses to provide a holistic view of market competitiveness and operational frameworks.

Market Dynamics

The study identifies the growing adoption of inhaler devices and biologics as key market drivers, fueled by their efficacy and patient compliance. However, high R&D expenses and stringent regulatory requirements act as restraints. The competitive rivalry is intense, with major players investing in novel therapies and strategic collaborations to maintain market share. The industry value chain analysis reveals the critical roles of raw material suppliers, manufacturers, and distributors in ensuring product availability.

Market Segmentation Analysis

The Global Bronchodilator Drug Market segments the market by disease type and administration route. Asthma and COPD dominate the disease type segment due to their high prevalence, while inhalers lead the administration route segment for their targeted delivery and rapid onset. Geographically, North America holds the largest share, driven by advanced healthcare infrastructure and high disease burden, while Asia Pacific exhibits the fastest growth due to rising awareness and improving access to care.

Competitive Environment and Analysis

The Global Bronchodilator Drug Market study emphasizes the competitive landscape, spotlighting key players such as GlaxoSmithKline plc, AstraZeneca plc, and Novartis AG. Recent developments highlight strategic moves by these companies to strengthen their portfolios. For instance, GlaxoSmithKline has advanced its triple-therapy inhaler, Trelegy Ellipta, with expanded approvals in multiple regions for COPD management, enhancing its market penetration. Similarly, AstraZeneca's Fasenra, a biologic for severe asthma, has gained traction through new clinical data demonstrating its efficacy in reducing exacerbations, positioning it as a competitive alternative in the asthma segment. These innovations underscore the focus on personalized therapies and combination treatments. The study also examines emerging players like Verona Pharma, which is progressing its ensifentrine nebulized therapy for COPD, potentially disrupting the market with a novel mechanism of action. Mergers, acquisitions, and collaborations, such as Novartis' partnerships for digital health integration, further intensify competition, as analyzed through the vendor competitiveness matrix.

Company Profiles

Detailed profiles of major players, including F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Merck & Co., Inc., Pfizer Inc., and Abbott, provide insights into their strategies, product pipelines, and market positioning. These profiles highlight how companies leverage R&D, regulatory approvals, and geographic expansion to sustain growth in the Global Bronchodilator Drug Market.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation

By Disease Type

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others

By Route of Administration

  • Oral
  • Injection
  • Inhaler

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Overview
  • 1.2. COVID-19 Impact
  • 1.3. Market Definition
  • 1.4. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Bronchodilator Drug Market Analysis, By Disease Type

  • 5.1. Introduction
  • 5.2. Asthma
  • 5.3. Chronic Obstructive Pulmonary Disease (COPD)
  • 5.4. Others

6. Global Bronchodilator Drug Market Analysis, By Route of Administration

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Injection
  • 6.4. Inhaler

7. Global Bronchodilator Drug Market Analysis, By Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. UAE
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. Japan
    • 7.6.3. South Korea
    • 7.6.4. India
    • 7.6.5. Thailand
    • 7.6.6. Taiwan
    • 7.6.7. Indonesia
    • 7.6.8. Others

8. Competitive Environment and Analysis

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. Company Profiles

  • 9.1. F. Hoffmann-La Roche Ltd
  • 9.2. Gilead Sciences, Inc.
  • 9.3. GlaxoSmithKline plc.
  • 9.4. Merck & Co., Inc.
  • 9.5. Novartis AG
  • 9.6. Verona Pharma plc
  • 9.7. Pfizer Inc.
  • 9.8. Abbott
  • 9.9. AstraZeneca plc